News & Events
< Back to News Overview
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate in Drug-Resistant CML Patients with the T315I Mutation
09 / 12 / 2008
ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today positive interim clinical data from 44 patients enrolled in its ongoing phase 2/3 trial of omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients with the T315I mutation.
Clinical investigators reported that subcutaneous omacetaxine was generally well tolerated and demonstrated durable complete hematological and cytogenetic responses in patients who had failed to respond to the current front-line treatment, imatinib mesylate (Gleevecr), and who have the T315I mutation. There are currently no effective drug treatments for the increasing number of patients with the T315I mutation, and it is acknowledged as an important therapeutic challenge in the treatment of CML.
Dr. Jorge Cortes, Professor of Medicine and Deputy Chair, Department of Leukemia at The University of Texas, MD Anderson Cancer Center in Houston, presented data today on behalf of a team including investigators from ChemGenex and leading U.S. and European research centers in a poster discussion session at the American Society of Hematology (ASH) 50th Annual Meeting in San Francisco, California.
Data were presented from 44 patients: 25 in chronic phase, 11 in accelerated phase and 8 in blast phase. Highlights of the data were:
Complete hematologic responses (CHR) in 80% of chronic phase patients, median response duration 11.5+ months (range 3.5-25.4+ months)
Major cytogenetic responses (MCyR) in 20% of chronic phase patients, median response duration 4.8+ months (range 0.3-9.7+ months)
Progression Free Survival (PFS) rates for chronic phase patients of 80% at 1 year and 70% at 2 years
Hematologic responses in 45% of accelerated phase patients (median duration 9.6+ months) and 13% of blast phase patients
Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect, reversible and transient myelosuppression, rarely results in serious clinical complications
"Omacetaxine continues to be a promising candidate for the treatment of CML patients with the T315I mutation, a common mutation in patients who have failed Gleevecr (imatinib) therapy and one for which there are no available therapies," said Dr. Cortes. "The clinical trial data we have presented demonstrates the ability of omacetaxine to induce durable clinical remissions in T315I+ CML patients and the elimination of the T315I clone in the majority of patients studied."
T315I-positive patients represent a significant and growing unmet medical need in CML, and omacetaxine continues to demonstrate impressive clinical benefits for patients with this mutation," said Dr. Greg Collier, ChemGenex's Managing Director and Chief Executive Officer. "This data presentation at ASH is another significant milestone for the company, being a strong indication of the data that will comprise the clinical section of our New Drug Application (NDA) to the FDA next year. We are on track to complete clinical trial enrollment by the end of this year, and we anticipate completing our rolling NDA submission for omacetaxine by mid 2009."
Clinical investigators reported that subcutaneous omacetaxine was generally well tolerated and demonstrated durable complete hematological and cytogenetic responses in patients who had failed to respond to the current front-line treatment, imatinib mesylate (Gleevecr), and who have the T315I mutation. There are currently no effective drug treatments for the increasing number of patients with the T315I mutation, and it is acknowledged as an important therapeutic challenge in the treatment of CML.
Dr. Jorge Cortes, Professor of Medicine and Deputy Chair, Department of Leukemia at The University of Texas, MD Anderson Cancer Center in Houston, presented data today on behalf of a team including investigators from ChemGenex and leading U.S. and European research centers in a poster discussion session at the American Society of Hematology (ASH) 50th Annual Meeting in San Francisco, California.
Data were presented from 44 patients: 25 in chronic phase, 11 in accelerated phase and 8 in blast phase. Highlights of the data were:
Complete hematologic responses (CHR) in 80% of chronic phase patients, median response duration 11.5+ months (range 3.5-25.4+ months)
Major cytogenetic responses (MCyR) in 20% of chronic phase patients, median response duration 4.8+ months (range 0.3-9.7+ months)
Progression Free Survival (PFS) rates for chronic phase patients of 80% at 1 year and 70% at 2 years
Hematologic responses in 45% of accelerated phase patients (median duration 9.6+ months) and 13% of blast phase patients
Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect, reversible and transient myelosuppression, rarely results in serious clinical complications
"Omacetaxine continues to be a promising candidate for the treatment of CML patients with the T315I mutation, a common mutation in patients who have failed Gleevecr (imatinib) therapy and one for which there are no available therapies," said Dr. Cortes. "The clinical trial data we have presented demonstrates the ability of omacetaxine to induce durable clinical remissions in T315I+ CML patients and the elimination of the T315I clone in the majority of patients studied."
T315I-positive patients represent a significant and growing unmet medical need in CML, and omacetaxine continues to demonstrate impressive clinical benefits for patients with this mutation," said Dr. Greg Collier, ChemGenex's Managing Director and Chief Executive Officer. "This data presentation at ASH is another significant milestone for the company, being a strong indication of the data that will comprise the clinical section of our New Drug Application (NDA) to the FDA next year. We are on track to complete clinical trial enrollment by the end of this year, and we anticipate completing our rolling NDA submission for omacetaxine by mid 2009."